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ABSTRACT  1 
Suppressor of cytokine signaling 3 (SOCS3) is a negative regulator of leptin signaling. We 2 
previously showed that the chronic effects of leptin on blood pressure (BP) and glucose 3 
regulation are mediated by stimulation of pro-opiomelanocortin (POMC) neurons. In this 4 
study, we examined the importance of endogenous SOCS3 in POMC neurons in control of 5 
metabolic and cardiovascular function and potential sex differences. Male and female 6 
SOCS3flox/flox/POMC-Cre mice in which SOCS3 was selectively deleted in POMC neurons 7 
and control SOCS3flox/flox mice were studied during a control diet (CD) or high fat diet (HFD) 8 
and during chronic leptin infusion. On CD, male and female SOCS3flox/flox/POMC-Cre mice 9 
were lighter in body weight despite similar food intake compared to control mice. Male 10 
SOCS3flox/flox/POMC-Cre mice exhibited increased energy expenditure. BP and heart rate 11 
were similar in male and female SOCS3flox/flox/POMC-Cre and control mice on CD. On a HFD, 12 
male and female SOCS3flox/flox/POMC-Cre mice showed attenuated weight gain. Female 13 
SOCS3flox/flox/POMC-Cre mice exhibited greater HFD-induced elevations in baseline BP and 14 
BP responses to air jet stress test compared to control mice. Chronic leptin infusion 15 
produced similar responses in all groups for food intake, body weight, oxygen consumption, 16 
blood glucose, BP and heart rate. Thus, SOCS3 deficiency in POMC neurons influences 17 
body weight regulation in CD and HFD and differentially affects BP and energy balance in a 18 
4 
 
sex specific manner, but does not amplify the dietary, glycemic or cardiovascular effects of 1 
leptin.  2 
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 4 
INTRODUCTION 5 
Suppressor of cytokine signaling 3 (SOCS3) is a cytoplasmic protein that belongs to 6 
the family of inducible negative regulators of cytokine signaling and is expressed in various 7 
tissues including brain, muscle and adipose tissue. Expression of SOCS3 is induced by 8 
several cytokines such as leptin, interleukin (IL)-1, and IL-10. In the leptin receptor signaling 9 
pathway, activated SOCS3 binds to phosphorylated tyrosine residues and inhibits leptin 10 
receptors downstream activation of Janus kinase (JAK) tyrosine kinase and signal 11 
transducer and activator of transcription 3 (STAT3) (3, 6, 12, 26). These effects of SOCS3 to 12 
inhibit JAK and STAT3 are believed to negatively regulate leptin signaling and may 13 
contribute to development of resistance to leptin’s anorexic and metabolic effects in obesity 14 
(2, 3, 22). Mice with central nervous system SOCS3 deficiency are resistant to diet-induced 15 
obesity (17), suggesting a role for SOCS3 in body weight regulation in obesity. 16 
Pro-opiomelanocortin (POMC) neurons, located within the arcuate nucleus (ARC) of 17 
the hypothalamus and in the nucleus tractus solitarius (NTS) of the brainstem, are thought to 18 
be important targets for leptin’s effects on appetite, blood glucose, and blood pressure (BP) 19 
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regulation (15, 16, 21). We previously showed that POMC neuronal specific deletion of leptin 1 
receptors abolished leptin’s ability to increase BP and to reduce fasting insulin and glucose 2 
levels (8). However, the importance of endogenous SOCS3 in POMC neurons for regulation 3 
of BP and metabolic functions is still unclear, and there have been no detailed studies, to our 4 
knowledge, on potential sex differences in metabolic and cardiovascular regulation by 5 
SOCS3 in POMC neurons. 6 
The main goal of the current study was to examine the impact of SOCS3 deficiency 7 
in POMC neurons on metabolic and cardiovascular regulation in male and female mice fed a 8 
regular control diet (CD) or a high fat diet (HFD). We also determined whether POMC 9 
neuronal SOCS3 deficiency amplifies the dietary, metabolic and cardiovascular effects of 10 
chronic hyperleptinemia.  11 
Our results indicate that SOCS3 deficiency in POMC neurons influences weight 12 
regulation in CD and HFD and differentially affects BP and energy balance in a sex specific 13 
manner, but does not amplify the dietary, glycemic or cardiovascular effects of chronic leptin 14 
infusion.  15 
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MATERIALS AND METHODS 1 
Animals  2 
The experimental procedures described in this study followed the National Institutes 3 
of Health Guide for the Care and Use of Laboratory Animals and were approved by the 4 
Institutional Animal Care and Use Committee of the University of Mississippi Medical Center. 5 
SOCS3flox/flox mice (generously provided by Dr. George Booz, University of Mississippi 6 
Medical Center) have loxP sites flanking exon 2. These mice were crossed with 7 
heterozygotic POMC-Cre mice (generously provided by Dr. Joel Elmquist, University of 8 
Texas Southwestern Medical Center) that express Cre-recombinase specifically in POMC 9 
neurons. Mice that were homozygous for SOCS3flox/flox and expressed Cre-recombinase in 10 
POMC neurons were labeled SOCS3flox/flox/POMC-Cre, and littermate homozygous 11 
SOCS3flox/flox mice not expressing Cre-recombinase were used as controls. 12 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox mice are on a mixed C57BL/6 and 129S 13 
background. All the studies in female mice were carried out in random cycling females. 14 
Validation of SOCS3 deficiency in SOCS3flox/flox/POMC-Cre mice 15 
Validation of specific inactivation of SOCS3 in POMC neurons in SOCS3 16 
flox/flox/POMC-Cre mice has been previously reported (19). To further confirm that SOCS3 17 
was inactivated in POMC neurons of SOCS3 flox/flox/POMC-Cre mice, immunohistochemistry 18 
was performed to examine phosphorylated-STAT3 (p-STAT3), the primary pathway by which 19 
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SOCS3 influences leptin signaling(1). Studies were conducted in SOCS3flox/flox and 1 
SOCS3flox/flox/POMC-Cre mice injected with leptin (5 mg/kg, i.p.) or saline 45 minutes before 2 
euthanasia and brain collection. Immunohistochemistry staining was performed using p-3 
STAT3 antibodies (Cell Signaling, Danvers, MA) in frozen coronal brain sections (30 μm 4 
thick) to visualize the expression level of p-STAT3 in the arcuate nucleus of the 5 
hypothalamus. qRT-PCR was also performed to further examine SOCS3 and protein-6 
tyrosine phosphatase 1B (PTP1B) mRNA expression levels in brain cortex and 7 
hypothalamus of male and female SOCS3flox/flox/POMC-Cre and control mice. SOCS3flox/flox 8 
(n=4-6/group per sex) and SOCS3flox/flox/POMC-Cre mice (n=4-6/group per sex) were 9 
euthanized, the brains were quickly removed, and the hypothalamus and cortex were 10 
isolated on an ice-cold platform. Tissue samples were frozen immediately by immersion in 11 
liquid nitrogen and stored at -80oC.  Total RNA was extracted using RNase Mini Kit 12 
(QIAGEN, Germantown, MD) according to the manufacturer’s protocol and quantified by 13 
spectrophotometry. Total RNA was reverse transcribed by SuperScript VILO cDNA 14 
synthesis kit (Thermo Fisher Scientific, Waltham, MA). qRT-PCR was performed on 1 ng of 15 
RNA using a StepOne Plus qRT-PCR system with PowerUP SYBR green master mix 16 
(Thermo Fisher Scientific). The following primer pair was used to amplify mouse SOCS3: 5’-17 
GGACCAAGAACCTACGCATCCA-3’ (forward) and 5’-CACCAGCTTGAGTACACAGTCG-3’ 18 
(reverse) PTP1B: 5’-CGCCATGGAGATGGAGAAGG-3’ (forward) and 5’-19 
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GTCGAATGTCCTGGTAAATAGCC-3’ (reverse). Mouse 18S rRNA was used as an internal 1 
control to normalize the expression levels of the target genes and delta-delta CT method 2 
was used to calculate the fold changes of target genes in SOCS3flox/flox/POMC-Cre mice 3 
compared to sex matched SOCS3flox/flox control mice.    4 
Experimental protocols 5 
Between 6 and 17 weeks of age, male and female SOCS3flox/flox (n=9/group per sex) 6 
and SOCS3flox/flox/POMC-Cre (n=9/group per sex) mice were individually housed and fed a 7 
CD (Envigo Teklad Custom Diets, Madison WI. CA-170955, 4.0 kcal/g, 66% Kcal from 8 
carbohydrate; 16% Kcal from fat; 18% Kcal from protein with 0.24-0.25% Na+ and 1% K+). 9 
Food intake and body weight were measured bi-weekly and weekly changes in body 10 
composition were analyzed using magnetic resonance imaging (4-in-1 EchoMRI-900TM, 11 
Echo Medical System, Houston, TX). When the mice were 18 weeks old, a fasting/refeeding 12 
protocol and food intake responses to an acute leptin injection were performed. At 20 weeks 13 
of age, oxygen consumption and fasting blood glucose, leptin and insulin concentrations 14 
were measured during baseline and during a 7-day leptin infusion. A glucose tolerance test 15 
(GTT) was performed at 23 weeks of age.  16 
Separate groups of 23-week-old male and female SOCS3flox/flox and 17 
SOCS3flox/flox/POMC-Cre mice (n=11/group per sex) were implanted with radiotelemetry 18 
probes to measure BP and heart rate (HR). These mice were fed a HFD (Envigo Teklad 19 
9 
 
Diets, Madison, WI. TD-08811, 4.7 Kcal/g, 45% from fat) for 6 weeks. Food intake, body 1 
weight, BP and HR were measured twice each week. At the end of the 6 weeks of HFD, 2 
GTT, air jet stress test, fasting blood glucose, leptin and insulin concentrations were 3 
examined.  4 
Fasting/refeeding protocol and food intake responses to acute leptin injection 5 
At 18 weeks of age, groups of male and female SOCS3flox/flox (n=6/group per sex) and 6 
SOCS3 flox/flox/POMC-Cre mice (n=6/group per sex) were examined for daily food intake and 7 
body weight for 3 consecutive days as a baseline followed by a 24-hour fast. After the fasting 8 
period, the mice were given food ad libitum for 3 days, while daily food consumption was 9 
recorded during this refeeding period.  10 
After one week to recover from the fasting/refeeding protocol, the mice were injected 11 
with leptin (5 mg/kg, i.p.) or saline vehicle (0.2 mL) 1 hour before lights out (5:00 pm) and 12 
food intake was measured at 2, 4, 15, and 24 hours post-injection. A within-subjects design 13 
was used in this study. Changes in food intake following leptin injections were compared to 14 
saline injection in the same animals. 15 
Oxygen consumption measurements during chronic leptin infusion and after HFD 16 
 Male and female SOCS3flox/flox (n=7/group per sex) and SOCS3flox/flox/POMC-Cre mice 17 
(n=7/group per sex) were placed individually in metabolic cages (Promethion metabolic and 18 
behavioral system, Sable Systems International, Las Vegas, NV) to measure body weight, 19 
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food intake, feeding bouts (number of food intake events, defined as eating from food 1 
hopper by a significant difference before and after the eating event), energy expenditure 2 
(EE), respiratory quotient (RQ), and motor activity. Mice were acclimatized to the new 3 
environment for 3 days followed by 5 consecutive days of baseline recordings. Then, the 4 
mice were anesthetized with isoflurane and an osmotic minipump (model 1007D, Alzet, 5 
Cupertino, CA) was implanted i.p. to deliver leptin (4 µg/kg/min) for 7 consecutive days. 6 
Metabolic data were recorded during leptin infusion followed by a 5-day post-leptin recovery 7 
period. Blood samples (100 µL) were collected via a tail snip after 6 hours of fasting (8:00 8 
am to 2:00 pm) on day 5 of the baseline period, on day 7 of leptin infusion, and at the end of 9 
the recovery period to measure plasma glucose, leptin and insulin concentrations. 10 
Metabolic phenotypes including EE, RQ, and motor activity were measured for 7 11 
consecutive days in separate groups of 20-23 week-old SOCS3flox/flox and 12 
SOCS3flox/flox/POMC-Cre male and female mice fed a HFD for 5 weeks (n=4-6/group per sex).  13 
Oral Glucose Tolerance Test (GTT)   14 
D-glucose (3 mg/kg of lean tissue plus 1 mg/kg of fat mass) was administered by 15 
gavage after a 5-h fast in 23 week-old male and female SOCS3flox/flox (n=7/group per sex) 16 
and SOCS3flox/flox/POMC-Cre (n=10/group per sex). Blood samples were collected by tail 17 
snip and blood glucose was measured using glucose strips (ReliOn) at baseline, 15, 30, 60, 18 
90, and 120 minutes after glucose administration. An oral GTT test was also performed in 19 
11 
 
30-week-old male and female mice of each genotype that were fed a HFD for 6 weeks 1 
(n=7/group per sex). 2 
Acute air-jet stress test 3 
 Male and female SOCS3flox/flox (n=5/group per sex) and SOCS3flox/flox/POMC-Cre 4 
(n=6/group per sex) mice at 30 weeks of age were fed a HFD for 6 weeks and placed in 5 
special cages used for air-jet stress testing. Briefly, after a 2-hour period of acclimation to the 6 
cage, BP and HR were continuously measured by telemetry for 30 minutes before the air-jet 7 
stress test was applied. The air-jet stress test consisted of 2-second pulses of air delivered 8 
every 5 seconds during 5 consecutive minutes aimed at the forehead of the mice at an 9 
approximate distance of 5 cm using a 14 gauge needle opening at the front of the tube 10 
connected to compressed air. After the 5-minute air-jet stress, BP and HR continued to be 11 
measured for an additional 30-minute recovery period. Changes in BP and HR responses 12 
during the air-jet stress and recovery period were calculated compared to the baseline 13 
period (average of the last 10 minutes of baseline period before air-jet stress was initiated). 14 
We also calculated the areas under curves (AUCs) of the MAP during the air-jet stress and 15 
recovery periods using the following parameters: average change in MAP for each minute 16 
during the 5-minute air-jet stress test and for every 5 minutes during the 30-minute recovery 17 
period. 18 
Liver weight and fat/lean composition 19 
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Male and female SOCS3flox/flox (n=6/group per sex) and SOCS3flox/flox/POMC-Cre mice 1 
(n=6/group per sex) fed a HFD for 8 weeks were sacrificed at 31 weeks of age. Whole livers 2 
were harvested and weighed and then analyzed for fat and lean mass content using 3 
EchoMRI analyzer. 4 
MAP and HR responses to chronic leptin infusion in mice fed a CD  5 
Subgroups of 23 week old male and female SOCS3flox/flox (n=4/group per sex) and 6 
SOCS3flox/flox/POMC-Cre mice (n=5/group per sex) were implanted with telemeters. Briefly, 7 
mice were anesthetized with 2% isoflurane and a telemetry probe (TA11PA-C10, Data 8 
Science International, St. Paul, MN) was implanted in the left carotid artery and advanced 9 
into the aorta for measurement of BP and HR, 24 hours/day, using computerized methods 10 
(8). Ten days after recovery from surgery, five days of stable baseline BP and HR 11 
measurements were recorded. Then, the mice were anesthetized with isoflurane and an 12 
osmotic minipump (model 1002, ALZET) was implanted i.p. to deliver leptin (4 µg/kg/min) for 13 
14 days, followed by a 5-day recovery period. BP and HR were measured during the leptin 14 
infusion and recovery periods. Blood samples (100 µL) were collected via a tail snip after 6 15 
hours of fasting (8:00 am to 2:00 pm) during the control period (day 5), on day 13 of leptin 16 
infusion, and at the end of the recovery period to measure plasma glucose, leptin and insulin 17 
concentrations.  18 
Plasma Hormones and Glucose Measurements 19 
13 
 
Fasting plasma leptin and insulin concentrations were measured with ELISA kits 1 
(R&D Systems and Crystal Chem Inc., respectively), and plasma glucose concentrations 2 
were determined using a glucose analyzer (Beckman Coulter, CA). During GTTs, blood 3 
glucose levels were measured using glucose meter and glucose strips (ReliOn). 4 
Statistical analyses 5 
Data are expressed as means ± SEMs. Significant differences between two groups were 6 
determined by unpaired Student’s t-test. Significant differences between multiple groups 7 
were determined by one-way ANOVA followed by Tukey multiple comparisons tests. 8 
Significant differences between two groups over time were determined by two-way ANOVA 9 
with repeated measures. Bonferroni post-hoc multiple comparisons were used to compare 10 
the means between two different groups at the same time point after two-way ANOVA test. 11 
Statistical significance was accepted at a level of P<0.05. 12 
 13 
RESULTS 14 
SOCS3flox/flox/POMC-Cre mice had reduced SOCS3 mRNA expression in the arcuate 15 
nucleus and amplified effect of leptin to increase p-STAT3 expression 16 
Hypothalamus p-STAT3 staining after i.p. saline injection was similar in 17 
SOCS3flox/flox/POMC-Cre mice and SOCS3flox/flox control mice (Fig. 1, A and D). However 18 
after acute i.p. leptin injection, positive staining for p-STAT3, a major downstream signaling 19 
14 
 
pathway activated by leptin, was enhanced in the arcuate nucleus of the hypothalamus in 1 
SOCS3flox/flox/POMC-Cre mice (Fig. 1, E and F) compared to SOCS3flox/flox control mice (Fig. 2 
1, B and C).  3 
The qRT-PCR analysis showed that expression levels of SOCS3 mRNA in the 4 
hypothalamus of SOCS3flox/flox/POMC-Cre mice was significantly lower compared to control 5 
mice in both male and female (41 % less in males and 58 % less in female respectively, Fig. 6 
1, G and I). However, SOCS3 expression in brain cortex was not significantly different 7 
between groups. We also measured the mRNA expression levels of PTP1B, which is 8 
another leptin signaling negative regulator expressed in POMC neurons. In both 9 
hypothalamus and cortex of SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice, 10 
expression levels of PTP1B were similar between groups in both sexes (Fig. 1, H and J). 11 
SOCS3 deficiency in POMC neurons reduced body weight and fat mass in mice fed a 12 
CD 13 
Both male and female SOCS3flox/flox/POMC-Cre mice had significantly lower body 14 
weight compared to sex-matched control mice from 8 to 17 weeks of age. We also observed 15 
sex differences for weight gain between male and female SOCS3 flox/flox/POMC-Cre mice 16 
when compared to their respective controls each week. For instance, while the differences in 17 
body weight in males between groups were significant from 8 to 11 weeks of age; in female 18 
SOCS3 flox/flox/POMC-Cre mice, the differences in body weight became significant from 16 to 19 
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17 weeks with female SOCS3 flox/flox/POMC-Cre mice having a lower body weight (Fig. 2, A 1 
and D).  2 
EchoMRI scans showed that the lower body weight in male SOCS3 flox/flox/POMC-Cre 3 
mice was due mostly to reduced body fat content compared to controls (Fig. 2, B and C), 4 
whereas female SOCS3 flox/flox/POMC-Cre mice exhibited reduced fat and lean mass 5 
compared to control mice (Fig. 2, E and F).  6 
SOCS3 deficiency in POMC neurons did not alter food intake, refeeding response to 7 
prolonged fasting, or the acute anorexic action of leptin in mice fed a CD 8 
Average daily food intake from 8 to 17 weeks of age was not significantly different in 9 
SOCS3flox/flox/POMC-Cre and control mice (Fig. 3, A and D). These results suggest that the 10 
lighter body weight of SOCS3flox/flox/POMC-Cre mice may not be caused mainly by reduced 11 
food intake. To further examine whether food intake regulation was altered in 12 
SOCS3flox/flox/POMC-Cre mice, a test of 24 hours fasting followed by a 3-day refeeding 13 
period was performed. Compared to baseline before fasting, food intake increased 14 
significantly during the refeeding period in all groups (Fig. 3, B and E). The 3-day cumulative 15 
food intake during the refeeding period was not significantly different between genotypes for 16 
male or female mice. Despite similar daily food intake (Fig. 4, A and C), male and female 17 
SOCS3flox/flox/POMC-Cre mice exhibited different eating patterns compared to controls with 18 
reduced nighttime feeding bouts (Fig. 4, B and D). 19 
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In addition to examining the impact of SOCS3 inactivation in POMC neurons on food 1 
intake regulation under normal conditions and after prolonged fasting, we also investigated if 2 
reduced SOCS3 expression in POMC neurons potentiates the acute anorexic effect of leptin. 3 
Acute leptin injections, however, caused similar reductions in food intake in 4 
SOCS3flox/flox/POMC-Cre mice and controls of both sexes (Fig. 3, C and F). These 5 
observations indicate that POMC neuronal SOCS3 deficiency has minimal impact on food 6 
intake regulation and on leptin’s acute anorexic effect.  7 
SOCS3 deficiency in POMC neurons increased energy expenditure in male mice and 8 
reduced plasma insulin and RQ in female mice fed a CD 9 
Compared to control mice, male SOCS3flox/flox/POMC-Cre mice had significantly 10 
higher (~22%) daytime and nighttime energy expenditure when normalized for body weight, 11 
while no differences were observed in female mice (Fig. 5, A and D). Female SOCS3 12 
flox/flox/POMC-Cre mice exhibited reduced nighttime RQs and motor activity (Fig. 5,  E and F) 13 
compared to female control mice (0.85±0.02 vs. 0.90±0.01 and 104±3 vs 169±3 m/12 hrs, 14 
respectively), while no significant differences were found in male mice (Fig. 5, B and C).  15 
No differences in baseline fasting plasma concentrations of leptin, insulin, and 16 
glucose were observed between male control and SOCS3flox/flox/POMC-Cre when fed a CD. 17 
However, the fasting plasma insulin concentration in female SOCS3flox/flox/POMC-Cre mice 18 
was significantly lower than in controls (Table 1, 2). In male and female SOCS3flox/flox/POMC-19 
17 
 
Cre mice, the glucose tolerance and AUC during an oral GTT were similar to that measured 1 
in sex matched controls (Fig. 5, G to J). 2 
SOCS3 deficiency in POMC neurons did not alter leptin’s anorexic and glucose or 3 
insulin lowering effects in mice fed a CD  4 
To examine whether SOCS3 deficiency in POMC neurons amplifies the chronic 5 
effects of leptin on metabolic function and glucose regulation in mice fed a CD, we infused 6 
leptin for 7 days at a rate calculated to raise plasma leptin concentrations to those observed 7 
in obesity. As expected based on our previous studies (8, 11), leptin treatment reduced 8 
fasting plasma insulin and glucose concentrations in all groups of mice (Table 1, 2). 9 
Contrary to what we anticipated, although leptin treatment reduced glucose levels in both 10 
genotypes, the reduction in insulin levels was statistically significant only in control mice 11 
(Table 1, 2).  12 
Leptin infusion for 7 days had similar effects to reduce food intake and to cause small 13 
but not significant reductions in body weight in male and female control and 14 
SOCS3flox/flox/POMC-Cre mice (Table 1, 2).  Leptin infusion did not significantly alter energy 15 
expenditure in any of the groups but significantly reduced RQ in control female mice (Table 16 
1, 2). Motor activity was reduced in both control and SOCS3flox/flox/POMC-Cre mice during 17 
leptin infusion and this reduction was significantly greater in SOCS3flox/flox/POMC-Cre mice 18 
compared to controls for both male and female mice (Table 1, 2).   19 
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SOCS3 deficiency in POMC neurons attenuated HFD-induced weight gain without 1 
altering liver weight or liver fat content  2 
Previous studies have shown that CNS SOCS3 deletion confers resistance to diet-3 
induced obesity. Therefore, we fed SOCS3 flox/flox/POMC-Cre and control mice a HFD for 6 4 
weeks to test if selective inactivation of SOCS3 in POMC neurons would attenuate weight 5 
gain. Compared to controls, male and female SOCS3flox/flox/POMC-Cre mice showed 6 
significantly attenuated weight gain (35% and 37% lower body weight than controls, 7 
respectively, after 6 weeks on a HFD) (Fig. 6, A and D). In males, daily caloric intake for 8 
HFD was higher than in CD in both SOCS3flox/flox/POMC-Cre and control mice, with no 9 
significant differences between groups (Fig. 6, B). In female SOCS3flox/flox/POMC-Cre mice, 10 
daily caloric intake was lower than in CD and was significantly reduced compared to control 11 
mice after switching to HFD (Fig. 6, E).  12 
After 8 weeks on HFD, the mice were euthanized and liver was weighed and fat 13 
content measured. Despite differences in weight gain on HFD, liver weight and liver fat 14 
content were not significantly different in SOCS3flox/flox/POMC-Cre mice compared to 15 
SOCS3flox/flox control mice (Fig. 6, C and F).  16 
To further examine whether reduced body weight in POMC SOCS3 deficient mice 17 
after HFD was due to increased leptin signaling sensitivity, we performed metabolic studies 18 
to examine EE, RQ and motor activity after 5 weeks of HFD in POMC SOCS3 deficient mice 19 
19 
 
and control mice of both sexes. Energy expenditure per gram of body weight, RQ, and motor 1 
activity (Fig. 7, A, B and C) were slightly but not significantly increased in male 2 
SOCS3flox/flox/POMC-Cre mice compared to sex-matched control mice. In female 3 
SOCS3flox/flox/POMC-Cre mice, EE was also slightly increased (Fig. 7, D) and there was a 4 
significant increase in RQ accompanied by significantly lower motor activity compared to 5 
control mice (Fig. 7, E and F).     6 
SOCS3 deficiency in POMC neurons attenuated HFD-induced fasting 7 
hyperinsulinemia and hyperglycemia without affecting glucose tolerance  8 
Six weeks of HFD significantly increased plasma leptin levels similarly in all groups of 9 
male and female mice compared to CD (Fig. 8, A and D) although female mice exhibited 10 
lower plasma leptin levels on both diets compared to male mice. However, SOCS3 11 
deficiency in POMC neurons markedly attenuated HFD-induced hyperinsulinemia and 12 
hyperglycemia compared to control mice. Insulin levels in male and female 13 
SOCS3flox/flox/POMC-Cre mice were significantly lower (1.0±0.2 vs 2.2±0.6 ng/ml in males, 14 
and 0.6±0.1 vs 1.1±0.2 ng/ml in females) compared to control mice after 6 weeks of HFD 15 
(Fig. 8, B and E). Glucose levels were also significantly lower in female SOCS3 16 
flox/flox/POMC-Cre mice compared to female control mice after HFD (Fig. 8, F).   17 
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Although SOCS3 deficiency in POMC neurons protected against HFD-induced 1 
hyperinsulinemia and hyperglycemia under fasting conditions, it did not alter glucose 2 
tolerance during an oral GTT when compared to control mice (Fig. 8, G and H). 3 
SOCS3 deficiency in POMC neurons potentiated HFD-induced elevation in BP and 4 
cardiac responses to acute stress in female mice  5 
There were no significant differences in MAP and HR in male or female SOCS3 6 
flox/flox/POMC-Cre and SOCS3flox/flox control mice at baseline or during 6 weeks of HFD (Fig. 9, 7 
A and D; C and F). However, when we calculated the change in BP before and after HFD, 8 
MAP increased similarly by approximately 4 mmHg in males of both genotypes (Fig. 9, B). In 9 
contrast, the increases in MAP in female SOCS3 flox/flox/POMC-Cre mice were significantly 10 
higher than in female SOCS3flox/flox controls during HFD. As shown in (Fig. 9, E), MAP in 11 
female SOCS3 flox/flox/POMC-Cre mice increased by approximately 5 mmHg, whereas MAP 12 
did not change in female SOCS3flox/flox controls during HFD. Feeding a HFD for 6 weeks did 13 
not alter HR in any of the groups (Fig. 9, C and F).   14 
To test whether SOCS3 deficiency in POMC neurons alters cardiovascular 15 
responses to an acute pressor stress, we performed an air-jet stress test in male and female 16 
mice after 6-weeks of HFD. The increases in MAP and HR in response to the air-jet stress 17 
were similar in males from both genotypes (Fig. 10, A and B). Female control mice exhibited 18 
a lower MAP and HR responses compared to male control mice. However, female 19 
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SOCS3flox/flox/POMC-Cre mice showed significantly higher BP and HR responses compared 1 
to female control mice (32±3 vs 20±4 mmHg and 193±10 vs 101±10 bpm, respectively) (Fig. 2 
10, A and B). AUCs of MAP during and post stress were significantly higher in female 3 
SOCS3flox/flox/POMC-Cre mice compared to female controls (Fig. 10, D), whereas no 4 
difference between male SOCS3flox/flox/POMC-Cre mice compared to male controls were 5 
observed (Fig. 10, C). 6 
SOCS3 deficiency in POMC neurons did not alter the dietary and cardiovascular 7 
responses to chronic leptin infusion in mice fed a CD 8 
We also examined if the dietary and cardiovascular responses to a 14-day leptin 9 
infusion were altered in mice fed a CD. Body weight (Fig. 11, A and D) and daily food intake 10 
(Fig. 11, B and E) responses to chronic leptin treatment were similar in male and female 11 
mice of both genotypes with a significant reduction in cumulative food consumption (Fig. 11, 12 
C to F) during leptin infusion associated with approximately a 8% and 10% weight loss in 13 
males and females, respectively. Despite the weight loss, MAP in male and female mice of 14 
all groups did not fall; in fact, male and female SOCS3flox/flox/POMC-Cre mice showed a 15 
transient increase in MAP during the first 5 days of leptin treatment (Fig. 12, A and C), 16 
however, the increases were not significant. The changes of HR during leptin treatment were 17 
similar between SOCS3flox/flox/POMC-Cre mice and control mice (Fig. 12, B and D). These 18 
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results suggest that deficiency of SOCS3 in POMC neurons does not markedly amplify the 1 
chronic effects of leptin on BP and HR.   2 
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DISCUSSION 1 
 The main question addressed in this study was whether SOCS3 deficiency in POMC 2 
neurons had a significant impact on metabolic and cardiovascular regulation in male and 3 
female mice fed a CD or HFD. There are three major findings in this study: first, we 4 
demonstrated that SOCS3 deficiency in POMC neurons reduced body weight and fat mass 5 
without significant changes in daily food intake, fasting blood glucose and leptin 6 
concentrations in mice fed a CD. In POMC SOCS3 deficient mice fed a HFD, their body 7 
weight gain was also significantly attenuated and was associated with reduced caloric intake. 8 
Second, we found important sex differences in the metabolic and cardiovascular responses 9 
of POMC SOCS3 deficiency in mice fed a CD or HFD. Third, POMC SOCS3 deficiency, 10 
surprisingly, did not amplify the chronic effects of leptin to reduce food intake, improve 11 
glucose regulation, or to raise BP and HR.  Thus, our results indicate that SOCS3 in POMC 12 
neurons regulates body weight and energy balance as well as the BP responses to a HFD in 13 
a sex specific manner. However, we found no evidence that SOCS3 levels in POMC 14 
neurons alter the food intake, BP and HR responses to chronic leptin infusions that raised 15 
plasma levels to those observed in severe obesity.   16 
Role of SOCS3 in POMC neurons in regulating energy balance and body weight  17 
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Our data showed that when fed a CD or HFD, male and female SOCS3flox/flox/POMC-1 
Cre mice were lighter with less fat mass, and gained less weight compared to age matched 2 
control mice. These observations confirm that SOCS3 deficiency in POMC neurons confers 3 
resistance to diet-induced obesity (DIO) as reported in previous studies (2, 22) and 4 
demonstrate that SOCS3 levels in POMC neurons contribute to regulation of body weight 5 
and adiposity under normal conditions or during a HFD. 6 
The smaller weight gain observed in POMC SOCS3 deficient mice fed a HFD was 7 
due, at least in part, to lower caloric intake compared to control mice, which was more 8 
apparent in female mice. Metabolic phenotype measurements after HFD showed that EE 9 
and RQ were slightly elevated in both male and female POMC SOCS3 deficient mice 10 
compared to controls after 5 weeks of HFD. We also found significant reductions in 11 
plasma insulin and glucose concentrations in POMC SOCS3 deficient mice 12 
compared to control mice after a HFD. However, these changes were not observed 13 
in mice fed a control diet. These results are consistent with increased leptin 14 
sensitivity in POMC SOCS3 deficient mice but only when challenged with HFD.  15 
Although SOCS3 in POMC neurons may not play a major role in food intake 16 
regulation during a regular feeding regimen, it may contribute to regulation of caloric intake 17 
during a HFD. However, SOCS3 in POMC neurons does not appear to evoke sensitization 18 
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to the acute or chronic anorexic effects of leptin and does not alter the food intake response 1 
to refeeding after prolonged fasting. These observations are consistent with our previous 2 
findings showing nearly intact anorexic responses to chronic leptin infusion in mice lacking 3 
leptin receptors in POMC neurons (8) and suggest that other neurons are more important in 4 
mediating the effects of leptin to reduce food intake. Our meal pattern studies showed that 5 
total food intake was not significantly different in SOCS3flox/flox/POMC-Cre mice compared to 6 
control male or female mice. However, SOCS3flox/flox/POMC-Cre mice had significantly fewer 7 
meal bouts suggesting larger meal sizes in SOCS3flox/flox/POMC-Cre mice compared to 8 
control mice. Hypothalamic neurons are recognized to control meal size as well as overall 9 
food intake,  and leptin signaling in the arcuate nucleus has been reported to regulate meal 10 
size (14).  Results from our study suggest that SOCS3 in POMC neuron may also have an 11 
important role in modulating leptin’s effect on meal size. 12 
Another potential explanation for the lower body weight and attenuated weight gain of 13 
POMC SOCS3 deficient mice on CD or HFD is that they had elevated energy expenditure 14 
compared to control mice. In the present study, we measured oxygen consumption, an 15 
indirect assessment of energy expenditure, and found that male SOCS3flox/flox/POMC-Cre 16 
mice exhibited greater oxygen consumption than male control mice. Female POMC SOCS3 17 
deficient mice, although showing similar oxygen consumption as in female control mice, 18 
exhibited lower RQ values which may be interpreted as greater utilization of fat as the main 19 
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fuel source, thus contributing to reduced fat mass when compared to female controls. We 1 
observed significantly reduced motor activity with similar energy expenditure before and after 2 
chronic leptin infusion in POMC SOCS3 deficient mice. Although leptin reduced motor 3 
activity, it did not significantly alter total energy expenditure, perhaps due to leptin’s known 4 
counterbalancing effects to increase sympathetic activity which tends to increase metabolic 5 
rate. The net effect was unaltered energy expenditure. Taken together, these results indicate 6 
that SOCS3 in POMC neurons contributes to body weight regulation via a combined effect 7 
on appetite and energy balance and plays an important role in DIO.  8 
Role of SOCS3 in POMC neurons in glucose regulation 9 
Kievit et al (19) previously showed improved GTT and reduced plasma glucose and insulin 10 
concentrations in male POMC SOCS3 deficient mice compared to control mice fed regular 11 
diet or HFD. In contrast, we did not observe significant differences in GTT, fasting blood 12 
glucose and insulin, or plasma leptin concentration between male SOCS3flox/flox/POMC-Cre 13 
and control mice when fed a CD. This discrepancy may be due to different ages of the 14 
animals and different diet compositions. We did, however, observe lower fasting plasma 15 
insulin levels in SOCS3flox/flox/POMC-Cre mice than in control mice after feeding them a HFD 16 
for 6 weeks. These results suggest that SOCS3 in POMC neurons may have a significant 17 
27 
 
role in glucose and insulin regulation but SOCS3 deficiency cannot completely prevent the 1 
development of HFD-induced glucose intolerance. 2 
Role of POMC neuronal SOCS3 in blood pressure regulation  3 
DIO in both humans and rodents is associated with an increased risk of hypertension 4 
(15, 16).  Although the underlying molecular, cellular and hormonal mechanisms of obesity-5 
induced hypertension are not fully understood, previous studies from our lab and others 6 
suggest that elevated leptin levels may raise BP by increasing sympathetic nervous system 7 
(SNS) activity in male rats and mice (5, 15, 23). Leptin has been reported to increase BP by 8 
activation of leptin receptors in the dorsomedial hypothalamus (DMH) (20). However, we 9 
previously showed that leptin receptor in POMC neurons mediate much of the chronic 10 
effects of leptin to raise BP in male mice (8-11). For example, leptin receptor deficiency 11 
specifically on POMC neurons completely abolished the rise in BP that occurred in control 12 
mice during 7 days of leptin infusion (8).  13 
Because SOCS3 is a negative regulator of leptin receptors activation, we 14 
hypothesized that SOCS3 deficiency in POMC neurons would increase BP in obese mice 15 
fed a HFD. However, we found this was observed only in female POMC SOCS3 deficient 16 
mice when comparing BP changes before and after HFD, whereas male mice of both groups 17 
exhibited similar BP.  We also observed enhanced BP and HR responses to an acute air jet 18 
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stress in female but not male POMC SOCS3 deficient mice when compared to sex-matched 1 
controls, suggesting the existence of sex differences in the role of POMC SOCS3 in 2 
cardiovascular regulation. (18).  3 
Although the precise mechanisms for the sex differences in BP regulation observed 4 
in the present study are still unclear, it is possible that POMC SOCS3 deficient female mice 5 
are more sensitive to HFD-induced increases in aldosterone production and/or 6 
mineralocorticoid receptor (MR) activation (13). Studies by Huby el al.(18) suggest that leptin 7 
may increase BP in females via increases in aldosterone secretion and activation of MR. 8 
However, the role of aldosterone and MR activation in mediating the BP effects of leptin in 9 
female mice was not tested in the present study.  10 
Alternatively, POMC SOCS3 deletion in female mice may be associated with HFD-11 
induced SNS activation as we previously observed in male rodents (5). This possibility would 12 
be consistent with our finding that female mice with POMC SOCS3 deficiency have greater 13 
BP responses to acute stress. However, the mechanisms that mediate the greater BP 14 
responses to a HFD and acute stress are still uncertain and will require further investigation. 15 
Chronic leptin infusion in male rodents has been reported to reduce food intake and 16 
raises MAP and HR mainly via activation of the SNS (15). However, we did not observe 17 
significant differences in BP or HR responses to chronic leptin infusion in control mice or in 18 
POMC SOCS3 deficient mice. These surprising results do not support our hypothesis that 19 
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SOCS3 deficiency in POMC neurons substantially enhances the BP and HR effects of leptin. 1 
One possible explanation for these findings is the reduced body weight associated with 2 
SOCS3 deficiency in POMC neurons may offset the effects of leptin on BP. Further 3 
experiments utilizing weight-matched mice may be useful in determining whether POMC 4 
SOCS3 deficiency alters BP regulation independently of changes in body weight.  5 
Another possible explanation for the lack of enhanced BP responses to leptin is that 6 
SOCS3 signaling in POMC neurons may modulate the effects of additional factors (e.g. 7 
PTP1B (4), another leptin signaling inhibitor) that either inactivate POMC neurons or 8 
attenuate the effects of leptin on SNS activity, BP and HR regulation. It is also possible 9 
SOCS3 deficiency does not substantially enhance the activity of the downstream pathways 10 
associated with leptin receptor mediated SNS activation and BP regulation by POMC 11 
neurons. Although SOCS3 in known to inhibit STAT3 phosphorylation, it is not clear whether 12 
SOCS3 attenuates other leptin signaling pathways (e.g. SHP2)  possibly important in BP 13 
regulation as we previously showed SHP2 in POMC neurons also contributes to leptin's 14 
actions on BP, energy balance, and glucose regulation (9).  15 
Sex difference in regulation of glucose, energy balance and blood pressure by SOCS3 16 
in POMC neurons  17 
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Accounting for sex differences in the design of experimental studies and 1 
interpretation of results is increasingly recognized as an important step in developing 2 
translational approaches to prevention and treatment of human diseases. As discussed 3 
previously, an important finding of our study is there were sex differences in some of the 4 
metabolic and cardiovascular effects of POMC SOCS3 deficient mice compared with control 5 
mice. For example, we found higher energy expenditure only in male POMC SOCS3 6 
deficient mice compared to controls and a reduced motor activity and RQ was observed in 7 
female POMC SOCS3 deficient mice fed a CD. Also female mice with POMC neuronal 8 
SOCS3 deficiency had increased MAP and BP response to air jet stress compared with 9 
female control mice fed a chronic HFD. In contrast, BP in male POMC SOCS3 deficient and 10 
control mice did not differ when they were fed a HFD. Quantitative differences in SOCS3 11 
expression and/or deletion in males and females might explain some of the sex differences 12 
observed in our study but are unlikely to fully account for qualitative differences. Different 13 
expression levels of NPY/AGRP and POMC in the hypothalamus of male and female mice 14 
may contribute to the observed phenotype differences (7, 25) but this was not tested in the 15 
present study. Although our studies were not designed to investigate the mechanisms 16 
responsible for sex differences in SOCS3 signaling and POMC neuronal control of 17 
metabolism and BP, they further emphasize the need to account for sex as a biological 18 
variable in future studies of CNS regulation of metabolic and cardiovascular function (24). 19 
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 1 
Perspectives and Significance: 2 
Our study indicates that SOCS3 deficiency in POMC neurons attenuates weight gain 3 
and adiposity, and increases energy expenditure in males while reducing RQ in female mice. 4 
We also found that POMC neuronal SOCS3 deficiency in female mice increased BP as well 5 
as the HR and BP stress responses associated with a HFD despite less weight gain. Our 6 
findings, therefore, suggest that SOCS3 in POMC neurons has an important role in 7 
regulating body weight, daily energy balance and BP in a sex specific manner. Future 8 
studies are needed to assess mechanisms responsible for sex differences in SOCS3 9 
signaling and POMC neuronal control of metabolic and cardiovascular function. 10 
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Figure Legends 1 
Figure 1. Immunohistochemistry of pSTAT3 staining in the ARC of SOCS3flox/flox and 2 
SOCS3flox/flox/POMC-Cre mice injected i.p. with saline (A, D) or leptin (5 mg/kg, B, C, E, F).  3 
SOCS3 (G, I) and PTP1B (H, J) mRNA levels were quantified by qRT-PCR in hypothalamus 4 
of SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. (n=4-6/group per sex, *p<0.05 5 
compared to SOCS3flox/flox mice at the same brain area by t-test) 6 
 7 
Figure 2. Body weight and body fat/lean mass from 8 to 17 week of ages in male and female 8 
mice on CD. A. Body weight, B. Body fat mass, and C. Body lean mass in male 9 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. D. Body weight, E. Body fat mass, 10 
and F. Body lean mass in female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. 11 
(n=9 /group per sex, * P<0.05 between groups by 2-way ANOVA, # P<0.05 between groups 12 
at the same time point by Bonferroni post-hoc test) 13 
 14 
Figure 3. Average daily food intake, fasting-refeeding responses, and food intake responses 15 
to acute leptin injection in male and female mice on CD. A. Average daily food intake from 8 16 
to 17 weeks of age in male SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice, B. Daily 17 
food intake before and after fasting, and 24, 48 and 72 hours after refeeding in males, C. 18 
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Change of food intake compared to the saline control at 2, 4, 15 and 24 hours after acute 1 
leptin injection in males. D. Average daily food intake from 8 to 17 weeks of age in female 2 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice, E. Daily food intake before and after 3 
fasting, and 24, 48 and 72 hours after fasting in females, F. Change of food intake compared 4 
to the saline control at 2, 4, 15 and 24 hours after acute leptin injection in females. Three-5 
day cumulative food intake in male and female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox 6 
control mice on CD after 24 hours of fasting. (n=6/group per sex, * P<0.05 compared to 7 
baseline by Bonferroni post-hoc test in SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control 8 
mice) 9 
 10 
Figure 4. Daytime and nighttime food intake and feeding bouts at baseline in male and 11 
female mice on CD. A. Food intake during daytime and nighttime in male 12 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. B. Feeding bouts during daytime 13 
and nighttime in male mice. C. Food intake during daytime and nighttime in female mice. D. 14 
Feeding bouts during daytime and nighttime in females. (n=7/group per sex, * P<0.05 15 
between groups by 2-way ANOVA, # P<0.05 between groups at the same time point by 16 
Bonferroni post-hoc test) 17 
 18 
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Figure 5. Daytime and nighttime energy expenditure, respiratory quotient, and motor activity 1 
measurement at baseline and glucose tolerance tests in male and female mice on CD. A. 2 
Daytime and nighttime energy expenditure normalized for body weight in male 3 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. B. Daytime and nighttime respiratory 4 
quotient in male mice. C. Daytime and nighttime motor activity in male mice. D. Daytime and 5 
nighttime energy expenditure normalized for body weight in female SOCS3flox/flox/POMC-Cre 6 
and SOCS3flox/flox control mice. E. Daytime and nighttime respiratory quotient in female mice. 7 
F. Daytime and nighttime motor activity in female mice. G. Blood glucose of male 8 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice measured over 120 minutes post-9 
glucose gavage in an oral GTT. H. Blood glucose AUC for male SOCS3flox/flox/POMC-Cre 10 
and SOCS3flox/flox control mice. I. Blood glucose of female SOCS3flox/flox/POMC-Cre and 11 
SOCS3flox/flox control mice measured over 120 minutes post-glucose gavage in an oral GTT. J. 12 
Blood glucose AUC for female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. 13 
(n=7/group per sex, * P<0.05, between groups by 2-way ANOVA and # P<0.05 between 14 
groups at the same time point by Bonferroni post-hoc test)  15 
 16 
Figure 6. Body weight gain, calorie intake, liver/body weight ratio and liver fat content in 17 
male and female mice on HFD. A. Body weight gain during 6 weeks of HFD in male 18 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. B. Average daily calorie intake 19 
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during 6 weeks of HFD in male mice. C. Ratio of liver weight to total body weight and liver fat 1 
weight after 8 weeks of HFD in male mice. D. Body weight gain during 6 weeks of HFD in 2 
female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. E. Average calorie intake 3 
during 6 weeks of HFD in female mice. F. Ratio of liver weight to total body weight and liver 4 
fat weight after 8 weeks of HFD in female mice. (n=11/group per sex, * P<0.05, between 5 
groups by 2-way ANOVA; # P<0.05, compared between groups at the same time point by 6 
Bonferroni post-hoc test) 7 
 8 
Figure 7. Daytime and nighttime energy expenditure, respiratory quotient, and motor activity 9 
measurements in male and female mice after 5 weeks of HFD. A. Daytime and nighttime 10 
energy expenditure normalized for body weight in male SOCS3flox/flox/POMC-Cre and 11 
SOCS3flox/flox control mice. B. Daytime and nighttime respiratory quotient in male mice. C. 12 
Daytime and nighttime motor activity in male mice. D. Daytime and nighttime energy 13 
expenditure normalized for body weight in female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox 14 
control mice. E. Daytime and nighttime respiratory quotient in female mice. F. Daytime and 15 
nighttime motor activity in female mice. (n=4-6/group per sex. * P<0.05, between groups by 16 
2-way ANOVA; # P<0.05, compared between groups at the same time point by Bonferroni 17 
post-hoc test)  18 
 19 
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Figure 8. Comparison of plasma leptin, insulin and fasting glucose concentrations and 1 
glucose tolerance tests in male and female mice fed CD or HFD. A. Plasma leptin 2 
concentrations in male SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice fed CD or 3 
HFD. B. Plasma insulin concentrations in male mice fed CD or HFD. C. Fasting Glucose 4 
concentrations of male mice fed CD or HFD. D. Plasma leptin concentrations of female 5 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice fed CD or HFD. E. plasma insulin 6 
levels on CD and HFD in females. F. Fasting Glucose concentrations in female mice fed CD 7 
or HFD. G. Blood glucose in male SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice 8 
measured over 120 minutes post-glucose gavage in an oral GTT. H. Blood glucose in female 9 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice measured over 120 minutes post-10 
glucose gavage in an oral GTT. (n=6/group per sex, * P<0.05, compared to the same 11 
genotype on a CD by Tukey multiple comparisons test.  # P<0.05, compared to SOCS3flox/flox 12 
mice on a HFD by Tukey multiple comparisons test.) 13 
 14 
Figure 9. MAP, changes of MAP compared to the baseline, and HR in male and female 15 
mice on HFD. A. Daily average MAP at baseline and 2, 4 and 6 weeks of HFD in male 16 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. B. Changes of MAP compared to 17 
baseline at 2, 4 and 6 weeks of HFD in male mice. C. HR at baseline and 2, 4 and 6 weeks 18 
of HFD in male mice. D. Daily average MAP during baseline and 2, 4 and 6 weeks of HFD in 19 
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female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. E. Changes of MAP 1 
compared to baseline at 2, 4 and 6 weeks of HFD in female mice.  F. HR at baseline and 2, 2 
4 and 6 weeks of HFD in female mice. (n=7/group per sex, * P<0.05 between groups by 2-3 
way ANOVA) 4 
 5 
Figure 10. Blood pressure and HR during air jet stress test in male and female mice on HFD. 6 
A. Maximum MAP increases during air jet stress compared to baseline in male and female 7 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. B. Maximum HR increases during 8 
air jet stress compared to baseline in male and female SOCS3flox/flox/POMC-Cre and 9 
SOCS3flox/flox control mice. C. MAP AUC for male SOCS3flox/flox/POMC-Cre and SOCS3flox/flox 10 
control mice during 5 minutes air jet stress and 30 minutes recovery after air jet. D. MAP 11 
AUC for female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice during 5 minutes air 12 
jet stress and 30 minutes recovery after air jet. (n=5-6/group per sex, * P<0.05 compared to 13 
female SOCS3flox/flox mice by unpaired Student’s t-test) 14 
 15 
Figure 11. Changes in body weight and food intake of male and female mice during 14 days 16 
of leptin infusion (4 µg/kg/min). A. Body weight during baseline, leptin infusion, and recovery 17 
in male SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. B. Daily food intake during 18 
baseline, leptin infusion and recovery in male mice. C. Cumulative food intake during 19 
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baseline, leptin infusion and recovery in male mice. D. Body weight during baseline, leptin 1 
infusion, and recovery in female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. E. 2 
Daily food intake changes during baseline, leptin infusion and recovery in female mice. F. 3 
Cumulative food intake during baseline, leptin infusion and recovery in female mice. 4 
 5 
Figure 12. Changes in MAP and HR of male and female mice during 14 days of leptin 6 
infusion (4 µg/kg/min). A. MAP during baseline, leptin infusion, and recovery periods in male 7 
SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. B. HR during baseline, leptin 8 
infusion, and recovery in male mice. C. MAP during baseline, leptin infusion, and recovery in 9 
female SOCS3flox/flox/POMC-Cre and SOCS3flox/flox control mice. D. HR during baseline, leptin 10 
infusion, and recovery in female mice. (n=4-5/grou/sex)   11 
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Table 1. Changes of metabolic parameters in male SOCS3flox/flox/POMC-Cre and 1 
SOCS3flox/flox control mice during 7 days of leptin infusion at 18 weeks of age 2 
Data are expressed as means ± SEMs and calculated as the average of last 4 days during control and leptin 3 
infusion period (shaded). * P<0.05 compared to baseline before leptin infusion; # P<0.05 compared to 4 
SOCS3
flox/flox
 control mice. 5 
Table 2. Changes of metabolic parameters in female SOCS3flox/flox/POMC-Cre and 6 
SOCS3flox/flox control mice during 7 days of leptin infusion at 18 weeks of age  7 
Parameter 
(Male) 
SOCS3
flox/flox
 
Control 
SOCS3
flox/flox
/POMC
-Cre 
SOCS3
flox/flox
 
Control   
+ Leptin 
SOCS3
flox/flox
/POMC-
Cre  
+ Leptin 
Body Weight, g 32.2±2.3 27.7±0.8 # 29.5±1.9 26.7±0.8 
Food Intake, g/day 2.6±0.3 2.9±0.4 1.9±0.3 2.5±0.3 
Plasma leptin, ng/ml 10.0±2.0 8.5±2.3 27.1±3.4 * 31.6±3.0 * 
Plasma insulin, ng/ml 0.46±0.10 0.42±0.09 0.21±0.08 * 0.32±0.07 
Plasma glucose, mg/dL 137±10 131±7 112±7 * 108±7 * 
Energy Expenditure, 
Kcal/day/g BW 
0.21±0.01 0.25±0.01 # 0.22±0.01 0.24±0.01 
RQ (VCO2/VO2) 0.84±0.03 0.83±0.01 0.81±0.02 0.81±0.01 
Motor Activity, m/day 134±14 165±24 114±13 87±10 *# 
Parameter 
(Female) 
SOCS3
flox/flox
 
Control 
SOCS3
flox/flox
/POMC-
Cre 
SOCS3
flox/flox
 
Control  
+ Leptin 
SOCS3
flox/flox
/POMC-
Cre  
+ Leptin 
Body Weight, g 23.0±0.9 21.4±0.6 # 21.0±0.6 20.3±0.6 
Food Intake, g/day 3.1±0.4 3.1±0.4 2.7±0.2 2.9±0.4 
Plasma leptin, ng/ml 4.5±1.1 4.2±1.3 30.6±8.5 * 43.9±9.7 * 
Plasma insulin, ng/ml 0.44±0.10 0.22±0.05 # 0.14±0.02 * 0.16±0.05 
Plasma glucose, mg/dL 131±9 119±5 98±7 * 101±8 * 
Energy Expenditure,   
Kcal/day/g BW  
0.33±0.03 0.36±0.02 0.33±0.04 0.37±0.01 
RQ (Vco2/Vo2) 0.86±0.01 0.82±0.01 # 0.83±0.01 * 0.82±0.01 
Motor Activity, m/day 212±13 134±13 # 161±14 * 80±8 *# 
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Data are expressed as means ± SEMs and calculated as the average of last 4 days during control (normal font) 1 
and leptin infusion period (shaded). * P<0.05 compared to baseline before leptin infusion; # P<0.05 compared to 2 
SOCS3
flox/flox
 control mice. 3 
